课题基金 / 基金详情

Delineation factors governing production of multi-component cytokines in clinical grade cells

Delineation factors governing production of multi-component cytokines in clinical grade cells
控制临床级细胞中多组分细胞因子产生的描绘因素
批准号:
2041107
负责人:
Michael Diehl
金额:
$40.0万
依托单位国家:
美国
项目类别:
Continuing Grant
财政年份:
2021
资助国家:
美国
项目状态:
未结题
起止时间:
2021-03-01 至 2025-02-28

项目摘要

项目成果

Michael Diehl的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Mammalian cells can produce therapeutic molecules known as biologics. Biologics can be used to treat cancer, auto-immune disorders and infectious viral disease. This project will address critical gaps in the ability engineer mammalian cells. These gaps limit cell therapy applications where cells are delivered to specific disease sites in the body in order to facilitate local biologic production. New methods to engineer clinical-grade cells for these types of applications will be developed. Complex biologics that are composed of multiple protein complexes will be the engineered products of these cells. Undergraduates, especially those from underrepresented minorities, will be trained through participation in the research.The main goals of this project are to identify and develop biosynthetic routes to circumvent bottlenecks that limit the secretion levels of fully-bioactive macromolecules. Multi-fragment, pro-inflammatory cytokines and clinical-grade cell lines will be used as model biologic and cell platforms. Protein expression will be manipulated precisely to identify bottlenecks that affect cytokine synthesis and heterodimerization. Multiple-gene manipulation strategies will be used to modulate the expression of additional genes in order to probe downstream secretion bottlenecks. Processes of particularly interest are proteolytic protein processing, folding, and vesicular trafficking. These experiments will test the overarching hypothesis that maximized secretion of multi-fragment proteins requires precision multi-gene translational control combined with the upregulation of multiple, downstream effector proteins along the secretion pathway. Engineered cells will be encapsulated in biopolymers. Their secretion stability and robustness will be evaluated. The extent to which these changes are linked to endoplasmic reticulum driven unfolded protein responses (UPR) is of primary interest.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
Development of Serum-Free Media for Cryopreservation of Hydrogel Encapsulated Cell-Based Therapeutics
开发用于水凝胶封装的细胞疗法冷冻保存的无血清培养基
DOI: 10.1007/s12195-022-00739-7
发表时间: 2022
期刊: Cellular and Molecular Bioengineering
影响因子: 2.8
作者: [Cui, Yufei, Nash, Amanda M., Castillo, Bertha, Sanchez Solis, Leonardo D., Aghlara-Fotovat, Samira, Levitan, Maya, Kim, Boram, Diehl, Michael, Veiseh, Omid]
通讯作者: Veiseh, Omid
CAREER: Integrated Biosynthetic and Single-Molecule Approaches to Investigate Collective Motor Protein Dynamics
  • 批准号:
    0643832
  • 项目类别:
    Continuing Grant
  • 资助金额:
    $54.9万
  • 财政年份:
    2007
  • 负责人:
    Michael Diehl
  • 依托单位:
国内基金
海外基金
上皮祖细胞应答巨噬细胞分泌因子IL-1β参与炎症微环境下输卵管纤毛分化障碍的机制研究
  • 批准号:
    82371691
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    张健
  • 依托单位:
KLF5诱导小鼠始发态多能性干细胞向滋养层干细胞转变的作用与机制研究
Beclin1介导的非自噬通路调控心肌细胞重编程的作用及机制研究
  • 批准号:
    32070728
  • 项目类别:
    面上项目
  • 资助金额:
    58.0万元
  • 批准年份:
    2020
  • 负责人:
    王丽
  • 依托单位:
生长素响应因子(Auxin Response Factors)在拟南芥雄配子发育中的功能研究
  • 批准号:
    31970520
  • 项目类别:
    面上项目
  • 资助金额:
    58.0万元
  • 批准年份:
    2019
  • 负责人:
    姚小贞
  • 依托单位: